Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

Moreover, while the effect of adjuvant therapy in node negative patients did not reach statistical significance, the absolute difference in survival (mOS: 103.2 vs. 61.6 months) is noteworthy and reminiscent of the CONKO-001 trial in which node negative pancreatic cancer patients experienced superior survival with adjuvant chemotherapy [ 34 ].

also in 111,027 other papers

More recently, a retrospective review from the MD Anderson Cancer Center showed a borderline significant improvement in survival with CRT in a subset of patients with advanced tumor stage (T3/T4), while a study from the Mayo Clinic found a survival benefit in patients with pathologic lymph node involvement [ 15 , 16 ].

also in 11,409 other papers